• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    2/25/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARQT alert in real time by email

    WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) --

    • Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and including a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returns
    • Full Year 2024 net product revenue for ZORYVE was $166.5 million, an increase of 471% over the prior year, setting the stage for sustained growth and strong financial position in 2025
    • ZORYVE is now the most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions combined in the United States
    • Supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream, 0.05%, submitted to the Food and Drug Administration (FDA) for the treatment of atopic dermatitis in children ages 2 to 5
    • Made a partial prepayment of $100 million of principal on $200 million of then outstanding debt with the ability to re-draw it in whole or in part

    WESTLAKE VILLAGE, Calif., Feb. 25, 2025  (GLOBE NEWSWIRE) – Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2024, and provided a business update.

    "Our success in 2024 was driven by growing ZORYVE momentum, including commercial launches for two new indications for ZORYVE, and our pricing and access strategy that led to strong commercial and government reimbursement. ZORYVE is the number one prescribed branded non-steroidal topical, due to its compelling value proposition of effectively and safely relieving multiple inflammatory skin conditions anywhere on the body for any duration," said Frank Watanabe, president and chief executive officer. "We are also continuing to advance our product pipeline and, along with strong stewardship of our financial resources and management of expenses, we believe we are well positioned to realize our mission of addressing unmet needs and the lack of innovation in medical dermatology."

    Program Updates / Key Milestones

    ZORYVE cream - a highly potent and selective phosphodiesterase-4 (PDE4) inhibitor in a once-daily cream formulation, approved in the United States for the treatment of plaque psoriasis and atopic dermatitis.

    • U.S. demand for ZORYVE cream 0.3% in plaque psoriasis continues to grow, with over 360,000 prescriptions filled since launch by over 14,000 unique prescribers, reflecting the high levels of patient and physician satisfaction with the ZORYVE cream clinical profile. ZORYVE cream is covered by the three largest Pharmacy Benefit Managers (PBMs) and multiple other commercial insurers, and during the quarter the Company expanded its Medicaid coverage to two additional states, Ohio and Illinois. The Company aims to obtain Medicaid coverage in additional states, as well as some Medicare coverage, during 2025. ZORYVE cream 0.3% saw significant gross-to-net (GTN) improvement in 2024 and has reached its steady state GTN.
    • Initial launch of ZORYVE cream 0.15% in atopic dermatitis has been strong with over 33,000 prescriptions filled since launch, and is covered as a line extension by two of the largest national PBMs. The Company anticipates continued improvement in coverage during 2025.
    • The Company submitted an sNDA for ZORYVE cream 0.05% to the FDA for the treatment of atopic dermatitis in children ages 2 to 5 with an anticipated target action date in Q4 of 2025, if accepted as submitted.

    ZORYVE foam - a once-daily foam formulation of topical roflumilast designed to overcome the challenges of delivering topical drugs in hair-bearing areas of the body, approved in the United States for the treatment of seborrheic dermatitis, and under FDA review for scalp and body psoriasis.

    • Demand for ZORYVE foam, 0.3% in seborrheic dermatitis continues to grow robustly each quarter, with over 246,000 prescriptions filled since launch, reflecting the high unmet need in this disease. ZORYVE foam is also covered by the three largest PBMs and has steadily improved coverage over the course of 2024. ZORYVE foam has gained Medicaid coverage in line with ZORYVE cream 0.3% and is nearing a steady state GTN.

    • The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, which was accepted by the FDA in September with a PDUFA action date set for May 22, 2025.

    ARQ-255 - a topical suspension formulation of ivarmacitinib, a potent and highly selective topical Janus kinase type 1 (JAK1) inhibitor, designed to preferentially deliver the drug deep into the hair follicle, in order to potentially treat alopecia areata at the site of inflammation.

    • In September 2024, the Company announced that it completed enrollment in a Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata, with data expected in H1 2025.

    ARQ-234 - a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 Receptor (CD200R), being developed as a potential biologic treatment in atopic dermatitis.

    • The Company has continued preclinical development efforts and is working towards submitting an Investigational New Drug application in 2025.

    Recent Corporate Highlights 

    • In October 2024, the Company made a partial prepayment of $100 million of principal on $200 million of then outstanding debt. The Company amended the $200 million term-loan with SLR Investment Corp. in August 2024, obtaining an option to prepay up to $100 million of the principal and re-draw it in whole or in part, at the Company's discretion.
    • In October 2024, Health Canada approved ZORYVE® (roflumilast) foam 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older, and the Company commenced sales in December.
    • In November 2024, ZORYVE cream 0.15% received Glamour's 2024 Health and Wellness Award for "Best Eczema Product".
    • Obtained one new U.S. patent in Q4 2024 related to topical roflumilast compositions.
    • In February 2025, announced a partnership with the iconic professional football player Odell Beckham Jr., to help raise awareness of seborrheic dermatitis and share his positive experience with ZORYVE foam.

    Fourth Quarter and Full Year 2024 Summary Financial Results

    Total revenues for the quarter ended December 31, 2024 were $71.4 million compared to $13.5 million for the corresponding period in 2023. The quarter ended December 31, 2024 included Other revenue of $2.0 million and a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returns. Total revenues for the year ended December 31, 2024 were $196.5 million compared to $59.6 million for the corresponding period in 2023. These year-over-year increases were due to strong unit demand growth as well as improvements in GTN sales deductions. In addition, 2024 and 2023 include Other revenue of $5.0 million and $30.0 million, respectively, related to the Huadong License and Collaboration Agreement. 2024 also includes Other revenue of $25.0 million from an upfront payment in connection with the Sato License Agreement, bringing Other revenue in 2024 to $30.0 million.

    Cost of sales for the quarter ended December 31, 2024 were $6.9 million compared to $2.2 million for the corresponding period in 2023. Cost of sales for the year ended December 31, 2024 were $19.1 million compared to $5.0 million for the corresponding period in 2023.

    Research and development (R&D) expenses for the quarter ended December 31, 2024 were $14.5 million compared to $23.8 million for the corresponding period in 2023. R&D expenses for the year ended December 31, 2024 were $76.4 million compared to $110.6 million for the corresponding period in 2023. These year-over-year decreases were due to decreased clinical development costs related to our topical roflumilast programs.

    Selling, general, and administrative (SG&A) expenses for the quarter ended December 31, 2024 were $57.6 million compared to $48.7 million for the corresponding period in 2023. SG&A expenses for the year ended December 31, 2024 were $229.4 million compared to $185.1 million for the corresponding period in 2023. These year-over-year increases were primarily due to higher sales force headcount and sales and marketing expenses related to the launches of ZORYVE.

    Net loss was $10.8 million, or $0.09 per basic and diluted share, for the quarter ended December 31, 2024 compared to $66.3 million, or $0.72 per basic and diluted share, for the corresponding period in 2023. Net loss was $140.0 million, or $1.16 per basic and diluted share, for the year ended December 31, 2024 compared to $262.1 million, or $3.78 per basic and diluted share, for the corresponding period in 2023.

    Cash, cash equivalents, restricted cash, and marketable securities were $228.6 million as of December 31, 2024, compared to $272.8 million as of December 31, 2023. Net cash used in operating activities was $0.7 million during the fourth quarter and $112.2 million during the full year 2024.

    Conference Call and Webcast

    Arcutis management will host a conference call and webcast today at 4:30 PM ET to discuss the financial results for the quarter and year and provide a business update. The webcast for this conference call may be accessed at the "Events" section of the Company's website. The replay of the webcast will be available on the Arcutis website following the call.

    About Arcutis

    Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis' dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential to address large markets with significant unmet need; the development, approval and potential commercialization of product candidates; the potential commercial success and growth of ZORYVE in plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, including market access and reimbursement, product demand growth and developments regarding GTN; and the timing of regulatory filings and potential approvals. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing, expenses, and success of our commercialization efforts, including uncertainty of future commercial sales and related items that can impact net sales, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the "Risk Factors" section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

    Contacts:

    Media

    Amanda Sheldon, Head of Corporate Communications

    [email protected]

    Investors

    Latha Vairavan, VP Finance and Corporate Controller

    [email protected]



    ARCUTIS BIOTHERAPEUTICS, INC.

    CondensedConsolidated Balance Sheets

    (In thousands)
     
     December 31, December 31,
      2024   2023 
        
    ASSETS   
    Current assets:   
    Cash and cash equivalents$71,335  $88,398 
    Restricted cash 617   925 
    Marketable securities 156,620   183,463 
    Trade receivable, net 73,066   25,807 
    Inventories 14,526   13,134 
    Prepaid expenses and other current assets 19,656   18,704 
    Total current assets 335,820   330,431 
    Property and equipment, net 1,041   1,539 
    Intangible assets, net 9,479   6,438 
    Operating lease right-of-use asset 1,953   2,361 
    Other assets 596   596 
    Total assets$348,889  $341,365 
    LIABILITIES AND STOCKHOLDERS' EQUITY   
    Current liabilities:   
    Accounts payable$14,220  $11,992 
    Accrued liabilities 65,973   33,941 
    Operating lease liability 820   735 
    Total current liabilities 81,013   46,668 
    Operating lease liability, noncurrent 2,562   3,382 
    Long-term debt, net 107,203   201,799 
    Other long-term liabilities 570   849 
    Total liabilities 191,348   252,698 
    Stockholders' equity:   
    Common stock 12   9 
    Additional paid-in capital 1,279,479   1,070,558 
    Accumulated other comprehensive loss (7)  4 
    Accumulated deficit (1,121,943)  (981,904)
    Total stockholders' equity 157,541   88,667 
    Total liabilities and stockholders' equity$348,889  $341,365 
            



        
    ARCUTIS BIOTHERAPEUTICS, INC.

    Condensed Consolidated Statements of Operations

    (In thousands, except share and per share data)
        
     Three Months Ended Year Ended 
     December 31, December 31,
      2024   2023   2024   2023 
     (unaudited)    
    Revenues:       
    Product revenue, net$69,360  $13,526  $166,542  $29,186 
    Other revenue 2,000   —   30,000   30,420 
    Total revenues 71,360   13,526   196,542   59,606 
            
    Operating expenses:       
    Cost of sales 6,905   2,246   19,128   4,987 
    Research and development 14,480   23,775   76,420   110,575 
    Selling, general, and administrative 57,607   48,674   229,391   185,145 
    Total operating expenses 78,992   74,695   324,939   300,707 
    Loss from operations (7,632)  (61,169)  (128,397)  (241,101)
            
    Other income (expense):       
    Other income, net 2,718   2,672   16,173   11,786 
    Interest expense (5,551)  (7,762)  (27,168)  (29,712)
            
    Loss before income taxes (10,465)  (66,259)  (139,392)  (259,027)
            
    Provision for income taxes$323  $25  $647  $3,113 
            
    Net loss$(10,788) $(66,284) $(140,039) $(262,140)
            
    Per share information:       
    Net loss per share, basic and diluted$(0.09) $(0.72) $(1.16) $(3.78)
    Weighted-average shares used in computing net loss per share, basic and diluted 124,918,560   92,580,106   120,957,633   69,305,487 
                    


    Primary Logo

    Get the next $ARQT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ARQT

    DatePrice TargetRatingAnalyst
    12/30/2024$19.00Buy
    H.C. Wainwright
    8/28/2024$15.00Buy
    Jefferies
    1/3/2024$4.00 → $8.00Neutral → Buy
    Mizuho
    10/26/2023$57.00 → $4.00Buy → Neutral
    Mizuho
    10/13/2023$32.00 → $6.00Buy → Neutral
    Goldman
    9/7/2022$46.00Buy
    Needham
    3/17/2022$45.00Buy
    Goldman
    3/2/2022$35.00 → $37.00Overweight
    Morgan Stanley
    More analyst ratings

    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis' common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted

      7/3/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

      The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD)Recommendation reflects ZORYVE's proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitorAmong newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis in AAD's focused guideline updateZORYVE is the first FDA-approved branded topical PDE4 inhibitor indicated for AD, plaque psoriasis, and seborrheic dermatitisAD impacts over 16 million adults in the Unit

      6/26/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

      Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitisAtopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first year WESTLAKE VILLAGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT, evaluating the safety and tolerability of investigational ZORYVE (ro

      6/10/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Welgus Howard G. sold $127,430 worth of shares (9,208 units at $13.84), decreasing direct ownership by 8% to 100,206 units (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      7/2/25 4:25:34 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Welgus Howard G. sold $135,574 worth of shares (10,139 units at $13.37), decreasing direct ownership by 8% to 109,414 units (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/20/25 4:32:21 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/17/25 5:45:01 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    SEC Filings

    See more
    • Arcutis Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - Arcutis Biotherapeutics, Inc. (0001787306) (Filer)

      6/17/25 4:52:21 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/15/25 5:41:18 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

      SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      5/8/25 5:59:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/17/25 5:45:01 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      6/6/25 8:44:37 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Heron Patrick J bought $68,821 worth of shares (5,040 units at $13.65) (SEC Form 4)

      4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

      5/23/25 4:04:50 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Arcutis Biotherapeutics with a new price target

      H.C. Wainwright initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $19.00

      12/30/24 7:23:09 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Arcutis Biotherapeutics with a new price target

      Jefferies initiated coverage of Arcutis Biotherapeutics with a rating of Buy and set a new price target of $15.00

      8/28/24 7:20:44 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Biotherapeutics upgraded by Mizuho with a new price target

      Mizuho upgraded Arcutis Biotherapeutics from Neutral to Buy and set a new price target of $8.00 from $4.00 previously

      1/3/24 7:32:19 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

      Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

      12/19/23 3:40:08 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

      Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

      12/15/23 5:01:31 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

      Industry veteran with deep commercial experience in dermatology and immunologyAyisha Jeter appointed Senior Vice President, Marketing and Market Access WESTLAKE VILLAGE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie. "We are t

      9/27/23 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces Leadership Transition

      Senior Vice President and Chief Commercial Officer (CCO) Ken Lock Stepping DownAyisha Jeter Appointed Interim CCO WESTLAKE VILLAGE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a leadership change. Ken Lock, who has served as Senior Vice President and Chief Commercial Officer (CCO) since October 2019, is stepping down to attend to personal matters effective June 2, 2023. During this transition period, Arcutis' Vice President of Market Access, Ayisha Jeter, has been appointed interim CCO. Mr. Lock's contributions t

      5/24/23 5:00:03 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

      WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Mas Matsuda, Esq. as General Counsel and Corporate Secretary. Mr. Matsuda joins Arcutis from Halozyme Therapeutics Inc. and succeeds Keith Klein, Esq. who announced his retirement after a successful 30-year industry career. In this role, Mr. Matsuda will oversee all legal and compliance matters for the Company. "On behalf of our entire team, we'd like to thank Keith for his considerable contributions to our efforts in establishing Arcutis as a le

      12/16/21 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Financials

    Live finance-specific insights

    See more
    • Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

      Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible resets and insurance changes, and excluding the non-recurring reduction in reserves for product return of $4.1 million reported in Q4 2024Continued demand growth for ZORYVE of 10%, solidifying its position as most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditionsAll three largest national Pharmacy Benefit Managers (PBMs) covering entire ZORYVE portfolio and Medicaid coverage continues to expandOn April 3, 2025, the patent litigation against Padagis was

      5/6/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

      WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report first quarter 2025 financial results and provide a business update on Tuesday, May 6, 2025 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET. A live webcast of the call and the presentation materials will be available on the "Events" section of The Company's website. An archived replay of the webcast will be available on the Arcutis investor website following th

      4/17/25 8:00:00 AM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Q4 2024 net product revenue for ZORYVE® (roflumilast) was $69.4 million, a 413% increase compared to Q4 of 2023 and a 55% increase compared to Q3 of 2024; driven by strong portfolio demand growth and including a non-recurring adjustment of $4.1 million due to a reduction in reserves for product returnsFull Year 2024 net product revenue for ZORYVE was $166.5 million, an increase of 471% over the prior year, setting the stage for sustained growth and strong financial position in 2025ZORYVE is now the most prescribed branded non-steroidal topical treatment across three major inflammatory skin conditions combined in the United StatesS

      2/25/25 4:00:00 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/14/24 7:50:59 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/13/24 4:30:25 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

      SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

      11/6/24 4:00:53 PM ET
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care